Comparative Pharmacology
Head-to-head clinical analysis: FLEXICORT versus MICORT HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLEXICORT versus MICORT HC.
FLEXICORT vs MICORT-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLEXICORT contains the active ingredient prednisolone, a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression, inhibition of phospholipase A2, and suppression of inflammatory mediators such as prostaglandins and leukotrienes.
Topical corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release, thereby exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Flexicort is not a recognized drug name in authoritative pharmacological databases. Please verify the correct generic name. Assuming hydrocortisone: Typical adult dose is 10-40 mg orally daily in divided doses or as a single morning dose. Route: oral. Frequency: once or twice daily.
Topical: Apply a thin film to affected area 2-4 times daily. Rectal: Insert one suppository (25 mg) rectally twice daily (morning and evening) for 2-3 weeks, then taper as needed.
None Documented
None Documented
8–12 hours; clinical context: once-daily dosing maintains therapeutic levels, with steady-state achieved within 2–3 days.
Terminal elimination half-life is 1.5-2.5 hours; clinical duration of action is longer due to genomic effects lasting 8-12 hours.
Renal excretion of inactive metabolites accounts for 95% of elimination; biliary/fecal excretion is minimal at 5%.
Renal (approximately 70% as inactive metabolites, <5% unchanged); fecal (approximately 30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid